An observational study in Multiple Sclerosis, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Multiple Sclerosis by Assiut University — 15 open to participants now, 15 under way, none of them phase 3. Multiple Sclerosis · Assiut University.
Among the 26 studies in Multiple Sclerosis by Assiut University, this one has the largest planned enrollment of the 24 observational ones that give a count, is the only one that started in 2027, is one of 24 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 24th registered.
3,269 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →15 of the 26 studies in Multiple Sclerosis by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 20–50 · Healthy volunteers
Assiut University
Ages 18+
Assiut University
Ages 18–55
Assiut University
Ages 18–55
Assiut University · Sites in Egypt
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 272 is above the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 48 across the 2 interventional studies, 100 across the 24 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Multiple Sclerosis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06770959Assiut UniversityFrequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study | 2026-12 |
| NCT06017726Assiut UniversityInsulin Resistance in Egyptian Patients With Multiple Sclerosis | 2026-12 |
| NCT07847086Assiut UniversityGait Pattern and Its Relation to Cognition and VEP in Multiple Sclerosis | 2027-09-26 |
| NCT07846943Assiut UniversityEpstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis | 2027-10 |
| NCT07826221Assiut UniversityPrevalence of Primary Headache in Multiple Sclerosis Patients | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Multiple Sclerosis by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple sclerosis (MS) is a chronic disease that mainly affects young adults, including women during their reproductive years. Women with MS may face important questions and concerns related to marriage, fertility, pregnancy, childbirth, breastfeeding, motherhood, and family planning. These decisions may be influenced by concerns about MS symptoms and disability, pregnancy-related changes in the disease, medications, possible effects on the baby, and the availability of appropriate reproductive health counseling and support.
This study aims to explore reproductive decision-making among women of reproductive age living with multiple sclerosis in Assiut Governorate, Egypt. The study will examine their experiences, concerns, fertility intentions, childbearing preferences, family planning practices, and experiences related to marriage, pregnancy, breastfeeding, and motherhood. It will also assess factors that may influence reproductive decisions, including disease-related characteristics, social and demographic factors, reproductive autonomy, and partner support among married women.
The study will use a sequential explanatory mixed-methods design. The quantitative component will include eligible married women with multiple sclerosis attending selected multiple sclerosis clinics in Assiut Governorate. Information will be collected through face-to-face interviews using structured questionnaires and validated assessment tools. The quantitative findings will be used to identify important patterns and factors associated with reproductive decision-making.
A qualitative component will then be conducted through in-depth interviews with selected women with multiple sclerosis to provide a deeper understanding of their experiences and concerns. Single women will be explored qualitatively to understand their perspectives regarding marriage, fertility, and future reproductive plans, while married women who participate in the quantitative component may also be invited for qualitative interviews. Participants will be selected to obtain a range of experiences and characteristics, and interviews will continue until sufficient information is obtained.
The study will provide a better understanding of the reproductive needs and concerns of women living with multiple sclerosis in Assiut Governorate. The findings may help identify gaps in reproductive health counseling and support and may contribute to the development of more patient-centered reproductive health services for women with multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system that predominantly affects individuals during their reproductive years. The increasing availability of effective disease-modifying therapies and improvements in the management of MS have allowed many women living with MS to consider marriage, pregnancy, and parenthood. However, reproductive decision-making may remain complex because women may have concerns about disease progression, disability, pregnancy and postpartum disease activity, effects of medications on pregnancy and breastfeeding, possible health risks to the child, and their ability to fulfil maternal and family responsibilities.
Reproductive decisions among women with MS may also be influenced by factors beyond the clinical characteristics of the disease. These may include age, marital status, educational and socioeconomic circumstances, family and social expectations, partner support, reproductive autonomy, previous reproductive experiences, access to appropriate counseling, and perceptions of the impact of MS on family life. Women may therefore make reproductive decisions within a complex interaction of medical, psychological, interpersonal, social, and demographic factors.
Despite the importance of reproductive health in women with chronic diseases, there is limited information about how women with MS in Egypt experience and make reproductive decisions, particularly within the social and cultural context of Upper Egypt. Understanding women's perspectives is important for identifying unmet reproductive health needs and improving counseling and support provided by healthcare professionals.
This study will use a sequential explanatory mixed-methods approach to explore reproductive decision-making among women of reproductive age living with MS in Assiut Governorate. The study will initially collect quantitative information from eligible married women with MS. The quantitative component will assess reproductive decision-making and related factors, including reproductive intentions and preferences, reproductive autonomy, partner support, and relevant sociodemographic and disease-related characteristics.
The quantitative findings will subsequently inform the qualitative component. In-depth interviews will be conducted with selected women with MS to provide a deeper understanding of the experiences, concerns, perceptions, and contextual factors underlying reproductive decisions. Married women participating in the quantitative component may be invited to participate in the qualitative interviews. Single women will be explored separately through the qualitative component to capture their perspectives regarding marriage, fertility intentions, future childbearing, and concerns related to reproductive life that cannot be adequately assessed through the quantitative component.
The qualitative sampling will use purposive maximum-variation sampling to include women with diverse sociodemographic, marital, and disease-related characteristics. These may include age, residence, educational level, employment, disease duration, disability severity, disease-modifying treatment, fertility intentions, motherhood status, and pregnancy experience after MS diagnosis. Interviews will continue until sufficient depth and diversity of information are achieved and thematic saturation is reached.
The qualitative interviews will explore women's experiences of living with MS and its perceived influence on marriage and intimate relationships, fertility intentions and timing of childbearing, desired family size, pregnancy and childbirth, breastfeeding, motherhood and childcare, and family planning and contraceptive decision-making. Participants will also be asked about their experiences of receiving reproductive health counseling and information related to pregnancy, contraception, breastfeeding, MS treatment, and potential risks to themselves or their children. The interviews will further explore the roles of partners, families, healthcare professionals, and the broader social context in shaping reproductive decisions.
Quantitative and qualitative findings will be interpreted together to develop a comprehensive understanding of reproductive decision-making among women living with MS. The qualitative findings will help explain and contextualize important quantitative patterns and may identify experiences or factors that are not captured by structured questionnaires.
The study is intended to generate evidence about the reproductive concerns, needs, and decision-making experiences of women living with MS in Assiut Governorate. The findings may help identify gaps in reproductive health information and counseling and may support the development of more responsive, patient-centered reproductive health services for women with MS. The study may also provide a basis for future research and interventions addressing reproductive health and family planning needs among women living with chronic neurological diseases.
The quantitative study population will include married women aged 18-49 with confirmed multiple sclerosis who attend the selected study sites during the study period. On the other hand, the qualitative population will include single, currently married, divorced and widowed/ever-married women aged 18-49 years with confirmed MS, as appropriate to the study sites and the qualitative sampling plan.
o Inclusion criteria
Women who are:
Able to communicate, agree to participate in the study and provide .
Women with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The quantitative study population will include married women aged 18-49 with confirmed multiple sclerosis who attend the selected study sites during the study period. On the other hand, the qualitative population will include single, currently married, divorced, or widowed/ever-married women aged 18-49 years with confirmed MS, as appropriate to the study sites and the qualitative sampling plan. Eligibility criteria: * Inclusion criteria Women who are * Within the reproduct age group (18-49 years). * With a confirm diagnosis of multiple sclerosis according to the 2024 Revised McDonald Criteria (31). * Able to communicate, agree to participate in the study and provide informed consent. * Exclusion Criteria Women with: * Severe cognitive impairment or psychiatric illness affects their ability to participate in the study. * Acute medical or neurological deterioration at the time of recruitment makes participation inappropriate or burdensome. * Any condition judged by the clinical team or
Motherhood/Pregnancy Choice and Worries Questionnaire (MPWQ) score
The Motherhood/Pregnancy Choice and Worries Questionnaire (MPWQ) will be used to assess women's experiences, choices, and worries related to motherhood and pregnancy in the context of multiple sclerosis, including concerns about pregnancy, motherhood, fertility, breastfeeding, childcare, and the potential effects of MS on reproductive decisions. The outcome will be reported as the total MPWQ score according to the scoring instructions of the instrument. The minimum and maximum possible scores and the direction of interpretation will be reported according to the validated version used in this study.
Time frame: At baseline (during the study interview)
Reproductive Concerns Scale score
The Reproductive Concerns Scale will be used to assess reproductive concerns related to multiple sclerosis, including concerns about fertility, pregnancy, maternal and fetal health, disease-related risks, treatment-related reproductive issues, and future reproductive plans. The outcome will be reported as the total Reproductive Concerns Scale score according to the scoring instructions of the instrument. The minimum and maximum possible scores and the direction of interpretation will be reported according to the validated version used in this study.
Time frame: At baseline (during the study interview)
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jun 2027; primary completion for Oct 2029, 28 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.